GlaxoSmithKline is in a spree of producing new diabetes and cancer drugs which it hopes will increase its sales this year. After the recent U.S. drug approvals it is starting to market two of its ...

The US Prescription Drug User Fee Act goal date for albiglutide is now set for April 15th 2014. This provides extra time for a full review of information submitted by GSK in response to the FDA's ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The furore over Avandia (rosiglitazone), GlaxoSmithKline's blockbuster drug for diabetes, illustrates how much the US drug business has changed over the past 3 years. Safety concerns over Avandia ...

GSK has been putting its money where its mouth is, and Witty says the last six drugs it launched in the ... in the last year or two as its flagship diabetes franchise, centred around insulin ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

It's a very busy and spooky Halloween eve today — several companies had big misses in earnings reported this morning. Let's ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

Oluwafemi Adelakun has provided a detailed explanation of the numerous benefits of herbal medicine, highlighting its ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Rosiglitazone, the diabetes drug taken by up to 100,000 people in the UK has been ... which was released to the market 10 years ago for people with type 2 diabetes. GlaxoSmithKline, which produces ...

New Delhi: GlaxoSmithKline's antibiotic drug Augmentin has risen to the top slot in the Indian pharmaceutical market, pushing the popular anti-diabetes drug Glycomet GP to the second slot.